Apollo Biowellness, Inc., Outlook for the Remainder of 2025
Apollo Biowellness (OTC Pink: KOAN) has announced several strategic initiatives for 2025-2026. The company has secured an exclusive distribution agreement with Revive Regenerative for its Evo Bio Brand in North America, targeting Med Spas, Injectors, and Plastic Surgeons. The company is also exploring distribution partnerships in Europe, Asia, and the Middle East.
Key upcoming developments include the launch of a shelf-stabilized biologic cosmetic brand in Q3 2025 for retail and direct-to-consumer channels, and a partnership with an Israeli biotech firm to develop placental-based biologics for pets launching in Q1 2026. The Evo Bio division is currently operating at a $2.2M annual run rate, with expectations for significant growth through 2025-2026.
Apollo Biowellness (OTC Pink: KOAN) ha annunciato diverse iniziative strategiche per il 2025-2026. L'azienda ha ottenuto un accordo esclusivo di distribuzione con Revive Regenerative per il suo marchio Evo Bio in Nord America, rivolto a Med Spa, iniettori e chirurghi plastici. Inoltre, sta esplorando partnership di distribuzione in Europa, Asia e Medio Oriente.
Tra i principali sviluppi previsti vi è il lancio di un marchio cosmetico biologico stabile sugli scaffali nel terzo trimestre del 2025, destinato ai canali retail e direct-to-consumer, e una collaborazione con una società biotech israeliana per sviluppare biologici a base placentare per animali domestici, con lancio previsto nel primo trimestre del 2026. La divisione Evo Bio attualmente opera con un fatturato annuo di 2,2 milioni di dollari, con aspettative di crescita significativa nel periodo 2025-2026.
Apollo Biowellness (OTC Pink: KOAN) ha anunciado varias iniciativas estratégicas para 2025-2026. La compañía ha asegurado un acuerdo exclusivo de distribución con Revive Regenerative para su marca Evo Bio en Norteamérica, dirigido a Med Spas, inyectores y cirujanos plásticos. También está explorando asociaciones de distribución en Europa, Asia y Medio Oriente.
Los desarrollos clave incluyen el lanzamiento de una marca cosmética biológica estable en estantería en el tercer trimestre de 2025 para canales minoristas y directos al consumidor, y una colaboración con una empresa biotecnológica israelí para desarrollar biológicos basados en placenta para mascotas, con lanzamiento previsto para el primer trimestre de 2026. La división Evo Bio opera actualmente con una tasa anual de 2,2 millones de dólares, con expectativas de un crecimiento significativo durante 2025-2026.
Apollo Biowellness (OTC Pink: KOAN)은 2025-2026년을 위한 여러 전략적 계획을 발표했습니다. 회사는 북미 지역의 Med Spa, 주사 전문가 및 성형외과 의사를 대상으로 하는 Evo Bio 브랜드에 대해 Revive Regenerative와 독점 유통 계약을 체결했습니다. 또한 유럽, 아시아, 중동 지역에서 유통 파트너십을 모색하고 있습니다.
주요 예정 사항으로는 2025년 3분기에 소매 및 직접 소비자 채널을 위한 선반 안정형 생물학적 화장품 브랜드 출시와 2026년 1분기 출시를 목표로 하는 이스라엘 바이오텍 기업과의 협력을 통한 반려동물용 태반 기반 생물학적 제제 개발이 포함됩니다. Evo Bio 부서는 현재 연간 220만 달러 매출을 기록하고 있으며, 2025-2026년 동안 상당한 성장이 기대됩니다.
Apollo Biowellness (OTC Pink : KOAN) a annoncé plusieurs initiatives stratégiques pour 2025-2026. La société a conclu un accord de distribution exclusif avec Revive Regenerative pour sa marque Evo Bio en Amérique du Nord, ciblant les Med Spas, les injecteurs et les chirurgiens plasticiens. Elle explore également des partenariats de distribution en Europe, en Asie et au Moyen-Orient.
Parmi les développements clés à venir, on compte le lancement d'une marque cosmétique biologique stable en rayon au troisième trimestre 2025, destinée aux canaux de vente au détail et direct au consommateur, ainsi qu'un partenariat avec une entreprise biotechnologique israélienne pour développer des biologiques à base de placenta pour animaux de compagnie, dont le lancement est prévu au premier trimestre 2026. La division Evo Bio fonctionne actuellement avec un taux de chiffre d'affaires annuel de 2,2 millions de dollars, avec des attentes de croissance significative entre 2025 et 2026.
Apollo Biowellness (OTC Pink: KOAN) hat mehrere strategische Initiativen für 2025-2026 angekündigt. Das Unternehmen hat eine exklusive Vertriebsvereinbarung mit Revive Regenerative für seine Evo Bio Marke in Nordamerika abgeschlossen, die sich an Med Spas, Injektoren und plastische Chirurgen richtet. Zudem werden Vertriebspartnerschaften in Europa, Asien und dem Nahen Osten geprüft.
Zu den wichtigsten bevorstehenden Entwicklungen gehört die Einführung einer regalstabilen biologischen Kosmetikmarke im dritten Quartal 2025 für den Einzelhandel und Direktvertrieb an Verbraucher sowie eine Partnerschaft mit einem israelischen Biotechnologieunternehmen zur Entwicklung von placentabasierten Biologika für Haustiere, die im ersten Quartal 2026 auf den Markt kommen sollen. Die Evo Bio Division arbeitet derzeit mit einer jährlichen Umsatzrate von 2,2 Mio. USD und erwartet ein deutliches Wachstum in den Jahren 2025-2026.
- Current Evo Bio division operating at $2.2M annual run rate
- Exclusive North American distribution agreement secured with Revive Regenerative
- New shelf-stable cosmetic product launch planned for Q3 2025
- Strategic shift to R&D and manufacturing focus while leveraging established distribution channels
- Geographic expansion planned across Europe, Asia, and Middle East markets
- New business model implementation may take time to show results
- Pet biologics product launch delayed until Q1 2026
- Heavy reliance on distribution partners for sales and marketing
North Bergen, New Jersey--(Newsfile Corp. - July 9, 2025) - Apollo Biowellness, Inc. (OTC Pink: KOAN) (the "Company"), as previously announced, the Company has officially entered into an exclusive distribution and marketing agreement for North America, only, with Revive Regenerative, Inc., for its Evo Bio Brand for Med Spas, Injectors, Plastic Surgeon, etc. In addition, the Company is in discussions with various other laser and device manufacturers in Europe, Asia and the Middle East for additional distribution of your biologic products in those various regions.
Evolutionary Biologics Ad Campaign
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10533/258139_53768fd164446b62_001full.jpg
The Company has plans to launch a consumer shelf stabilized biologic cosmetic brand before the end of the third quarter of 2025. It will be a shelf stabilized biologics cosmetic where no refrigeration is needed as our current Evo Bio Product requires, where we will be selling the product into retail or direct to consumer and e-commerce platforms, including TV shopping directly to consumers.
Lastly, the Company is in discussions with a substantial Israeli based biologic bio-tech manufacturer, to create the first placental based biologic focused on pets, dealing with various health issues surrounding dogs and cats, focused on joint issues arthritic issues and post-surgery issues. This new product will be launched into production and sales in the first quarter of 2026.
This new model and structure for the Company refocusing on R&D, production and manufacturing and wholesale distribution, will allow us to focus our attention on the creation of and development of the products, manufacturing of the products, maintaining IP and SOP's, by allowing sales and marketing to be handled by large companies with significant distribution capabilities.
The Company's currently operating division, Evo Bio, is currently operating at a
James W. Zimbler, President stated, "In furthering the new business model of the Company, of becoming an R&D, manufacturing production biologics company, selling through larger distribution channels allows us to focus on our core competency of development and procurement and brands, rather than focusing on managing the sales process, and allows us a larger expansion and scale"
You can follow and contact the Company on X at @ApolloBioKOAN.
About Apollo Biowellness, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.
Before using any of our products, you should always consult with your veterinarian and/or family doctor.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.
Corporate Contact
James W. Zimbler
President/CEO/Director
info@evolutionarybiologics.com
https://evobiologics.com/
631-806-1420
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258139
FAQ
What is Apollo Biowellness's (KOAN) current annual revenue run rate?
When will KOAN launch its new shelf-stabilized biologic cosmetic brand?
What is Apollo Biowellness's new distribution agreement for North America?
What new pet-focused product is KOAN developing?
What is Apollo Biowellness's new business strategy?
